PROTECTIVE IMMUNITY IN MICE TO PNEUMOCOCCAL POLYSACCHARI

对肺炎球菌生化特性的研究仍在继续。 自溶素与小鼠对肺炎球菌的保护性免疫 多糖-蛋白质结合物。几种肺炎链球菌的细胞表面 抗原被认为是毒力因子。有几个 蛋白抗原和毒素，包括肺炎溶血素、自溶素、肺炎球菌 表面蛋白A(PSPA)和其他次要抗原剂。分离出自溶素 从肺炎球菌R61株中分离、纯化。自溶素表现出 N-乙酰壁氨酸L-丙氨酸酰胺酶的主要酶活性。它是 参与调节肺炎链球菌肺炎溶血素的释放 细胞质。纯化后的自溶酶比活力 增加了143倍。得率为粗提物的0.9%。它 在SDS-PAGE中显示单一条带，相对分子质量为36,000。 肺炎链球菌9V PS或19F PS与载体蛋白的偶联 可产生足够的抗体预防肺炎球菌感染 在童年时期。肺炎溶血素和自溶酶可能是有效的 PS蛋白结合疫苗的载体。细菌的研究进展 免疫幼鼠的清除和抗体反应持续进行。 在早期生命中使用9V型或19F型PS-蛋白质偶联物 检测幼龄小鼠对肺炎球菌感染的保护性免疫。 在其他研究中，19F PS-PLY结合物在小鼠体内诱导了高水平的19F PS抗体 用放射免疫法测定幼龄小鼠。这些抗体诱导了快速的细菌 5x104CFU/剂量AS激发后19F细胞从血液中的清除 与未免疫的对照组相比。

Studies were continued on biochemical characterization of pneumococcal autolysin and protective immunity in mice to pneumococcal polysaccharide-protein conjugates. A number of pneumococcal cell-surface antigens are considered to be virulence factors. There are several protein antigens and toxins including pneumolysin, autolysin, pneumococcal surface protein A (PspA) and other minor antigens.Autolysin was isolated from pneumococcal R61 strain and purified. The autolysin exhibits the major enzymatic activity of N-acetylmuramic acid L-alanine amidase. It is involved in mediating the release of pneumolysin from pneumococcal cytoplasm. After purification, the specific activity of autolysin increased 143 fold. The yield was 0.9% of the crude extract. It exhibited a single band in SDS-PAGE, having a molecular weight of 36,000. Conjugation of pneumococcal type 9V PS or type 19F PS to a carrier protein may produce sufficient antibody for prevention of pneumococcal infection during childhood. Pneumolysin and autolysin may serve as effective carriers for PS-protein conjugate vaccines. Studies on bacterial clearance and antibody response were continued in young mice immunized with type 9V or type 19F PS-protein conjugates during early life to examine the protective immunity of young mice to pneumococcal infection. In other studies, a 19F PS-ply conjugate induced high 19F PS antibodies in young mice as measured by RIA . These antibodies induced rapid bacterial clearance of 19F cells from blood after challenge with 5 x 104 cfu/dose as compared to the non-immunized controls.